JP5737824B2 - 糖結合体ワクチン - Google Patents

糖結合体ワクチン Download PDF

Info

Publication number
JP5737824B2
JP5737824B2 JP2007547709A JP2007547709A JP5737824B2 JP 5737824 B2 JP5737824 B2 JP 5737824B2 JP 2007547709 A JP2007547709 A JP 2007547709A JP 2007547709 A JP2007547709 A JP 2007547709A JP 5737824 B2 JP5737824 B2 JP 5737824B2
Authority
JP
Japan
Prior art keywords
antigens
conjugate
protein
antigen
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007547709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008525423A5 (enExample
JP2008525423A (ja
Inventor
ジュディス， ジュセピ デル
ジュディス， ジュセピ デル
カリン バラルド，
カリン バラルド，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル, ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル
Publication of JP2008525423A publication Critical patent/JP2008525423A/ja
Publication of JP2008525423A5 publication Critical patent/JP2008525423A5/ja
Application granted granted Critical
Publication of JP5737824B2 publication Critical patent/JP5737824B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2007547709A 2004-12-24 2005-12-23 糖結合体ワクチン Expired - Fee Related JP5737824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0428394.1A GB0428394D0 (en) 2004-12-24 2004-12-24 Saccharide conjugate vaccines
GB0428394.1 2004-12-24
PCT/IB2005/004050 WO2006067632A2 (en) 2004-12-24 2005-12-23 Saccharide conjugate vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012267162A Division JP2013049717A (ja) 2004-12-24 2012-12-06 糖結合体ワクチン

Publications (3)

Publication Number Publication Date
JP2008525423A JP2008525423A (ja) 2008-07-17
JP2008525423A5 JP2008525423A5 (enExample) 2009-02-12
JP5737824B2 true JP5737824B2 (ja) 2015-06-17

Family

ID=34130952

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007547709A Expired - Fee Related JP5737824B2 (ja) 2004-12-24 2005-12-23 糖結合体ワクチン
JP2012267162A Withdrawn JP2013049717A (ja) 2004-12-24 2012-12-06 糖結合体ワクチン
JP2015105889A Pending JP2015155464A (ja) 2004-12-24 2015-05-25 糖結合体ワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012267162A Withdrawn JP2013049717A (ja) 2004-12-24 2012-12-06 糖結合体ワクチン
JP2015105889A Pending JP2015155464A (ja) 2004-12-24 2015-05-25 糖結合体ワクチン

Country Status (14)

Country Link
US (2) US20080260773A1 (enExample)
EP (1) EP1838345B1 (enExample)
JP (3) JP5737824B2 (enExample)
CN (1) CN101111261B (enExample)
AT (1) ATE492290T1 (enExample)
AU (1) AU2005317683B2 (enExample)
BR (1) BRPI0519232A2 (enExample)
CA (1) CA2594524C (enExample)
DE (1) DE602005025531D1 (enExample)
ES (1) ES2356670T3 (enExample)
GB (1) GB0428394D0 (enExample)
NZ (2) NZ556486A (enExample)
RU (1) RU2454244C2 (enExample)
WO (1) WO2006067632A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788794B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788798B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788797B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788796B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788795B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
AU2000278267A1 (en) 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
US7939087B2 (en) * 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
KR101838938B1 (ko) 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US20110189223A1 (en) * 2008-04-16 2011-08-04 Glaxosmithkline Biologicals S.A. Vaccine
JP2011524375A (ja) * 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
CN102215862B (zh) * 2009-06-16 2016-04-06 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
US8974799B2 (en) * 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP2482843A4 (en) * 2009-10-02 2013-05-15 Univ Iowa Res Found PROCESS FOR IMPROVED VACCINE IMMUNOGENICITY
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011123042A1 (en) * 2010-04-01 2011-10-06 Independent Pharmaceutica Ab Vaccination procedure and products for use therein
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
CA2849391A1 (en) * 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
CN103826657A (zh) 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
KR101839496B1 (ko) * 2011-06-01 2018-03-19 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
PH12014500093A1 (en) 2011-07-11 2014-03-17 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014008406A2 (en) 2012-07-05 2014-01-09 Children's Medical Center Corporation The bacterial biofilm matrix as a platform for protein delivery
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
MX2015004171A (es) * 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN104069504B (zh) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
CN104004085B (zh) * 2014-05-28 2017-01-11 山东大学 一种结核杆菌lam寡糖缀合物及其制备方法与应用
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
KR20180129926A (ko) * 2016-06-02 2018-12-05 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
WO2017219004A2 (en) * 2016-06-17 2017-12-21 Children's Medical Center Corporation Biofilm matrix-boosted vaccine
US11097000B2 (en) * 2016-10-03 2021-08-24 National Taiwan University Klebsiella pneumoniae capsule polysaccharide vaccines
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
US10729763B2 (en) * 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019014829A (es) * 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3167081A1 (en) 2020-02-06 2021-08-12 Luke T. Daum Immunogenic compositions to treat and prevent microbial infections
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
CN113150084B (zh) * 2021-03-23 2023-03-21 江苏坤力生物制药有限责任公司 一种纳米化的冠状病毒抗原及其应用
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
CN114767846B (zh) * 2022-04-21 2025-10-14 中国医学科学院医学生物学研究所 一种轮状非结构蛋白4在提高重组轮状病毒亚单位疫苗免疫功能中的应用
CN115721711B (zh) * 2022-10-28 2024-01-23 普大生物科技(泰州)有限公司 一种肺炎球菌荚膜多糖-带状疱疹病毒重组蛋白结合疫苗及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
NZ311000A (en) * 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
CN1215337A (zh) * 1995-06-23 1999-04-28 史密斯克莱·比奇曼生物公司 包含一种多糖抗原－载体蛋白共轭物和游离载体蛋白的疫苗
EP0969873B1 (en) * 1997-03-27 2006-06-07 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788794B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788798B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788797B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788796B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置
JPH0788795B2 (ja) 1985-09-10 1995-09-27 マツダ株式会社 エンジンの空燃比制御装置

Also Published As

Publication number Publication date
EP1838345B1 (en) 2010-12-22
AU2005317683B2 (en) 2012-04-26
ATE492290T1 (de) 2011-01-15
CA2594524A1 (en) 2006-06-29
JP2015155464A (ja) 2015-08-27
AU2005317683A1 (en) 2006-06-29
DE602005025531D1 (de) 2011-02-03
ES2356670T3 (es) 2011-04-12
NZ593954A (en) 2013-07-26
CA2594524C (en) 2015-05-19
JP2008525423A (ja) 2008-07-17
WO2006067632A3 (en) 2007-03-29
CN101111261A (zh) 2008-01-23
NZ556486A (en) 2011-07-29
US20080260773A1 (en) 2008-10-23
WO2006067632A2 (en) 2006-06-29
BRPI0519232A2 (pt) 2009-01-06
CN101111261B (zh) 2013-03-27
GB0428394D0 (en) 2005-02-02
RU2007127993A (ru) 2009-01-27
US20150165019A1 (en) 2015-06-18
JP2013049717A (ja) 2013-03-14
EP1838345A2 (en) 2007-10-03
RU2454244C2 (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
JP2015155464A (ja) 糖結合体ワクチン
TWI679987B (zh) 包含結合之莢膜醣抗原的免疫原組合物及其用途
JP5687405B2 (ja) 髄膜炎菌結合体ワクチン接種
JP2017057227A (ja) 免疫原性組成物に使用するための生分解性ポリマーおよびカチオン性多糖を含むミクロ粒子
US10046048B2 (en) Homogenous suspension of immunopotentiating compounds and uses thereof
JP6266000B2 (ja) 免疫原性組成物
JP6411378B2 (ja) Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
JP5718545B2 (ja) 髄膜炎菌結合体ワクチン接種
JP2015532276A (ja) 非直鎖状糖コンジュゲート
EP1644036A2 (en) Immunization method against neisseria meningitidis serogroups a and c
US12533418B2 (en) Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2007007686A (en) Saccharide conjugate vaccines
HK1229726B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130131

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140409

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150421

R150 Certificate of patent or registration of utility model

Ref document number: 5737824

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees